title: Impact of switching or initiating antipsychotic treatment on body weight during a 6-month follow-up in a cohort of patients with schizophrenia.
abstract: OBJECTIVE
  Although weight gain is one of the most widely studied adverse effects of second-generation antipsychotics, only relatively few studies have specifically evaluated the long-term effect of switching antipsychotic medication on body weight. We aimed to evaluate the impact of switching antipsychotics on body mass index (BMI) during a 6-month follow-up period in a large cohort of patients with schizophrenia.
  
  
  METHODS
  Data came from a 6-month prospective naturalistic survey in 6007 patients with schizophrenia.
  
  
  RESULTS
  We prospectively studied the effect on BMI of initiating or switching antipsychotic medication after 6 months of treatment among 3801 patients with schizophrenia in a real-life setting. Patients who were being treated with clozapine or olanzapine at baseline were more likely to experience a decrease in BMI during the follow-up period than the patients who were being treated with a conventional antipsychotic (odds ratio, 2.25 and 1.68, respectively). Patients treated with aripiprazole and, to a lesser extent, those treated with risperidone were more likely to experience a decrease in BMI during follow-up than patients treated with conventional antipsychotics (odds ratio, 2.96 and 2.06, respectively).
  
  
  CONCLUSIONS
  Our findings suggest that switching antipsychotics could be an effective strategy for reducing or preventing weight gain.
authors.affiliation: Assistance Publique-Hôpitaux de Paris, Department of Psychiatry, Corentin-Celton Hospital, Issy-les-Moulineaux, France. jean-pierre.schuster@ccl.aphp.fr
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Schuster
authors.forename: Delphine
authors.initials: D
authors.lastname: Raucher-Chéné
authors.forename: Cédric
authors.initials: C
authors.lastname: Lemogne
authors.forename: Frédéric
authors.initials: F
authors.lastname: Rouillon
authors.forename: Isabelle
authors.initials: I
authors.lastname: Gasquet
authors.forename: Denis
authors.initials: D
authors.lastname: Leguay
authors.forename: Fabien
authors.initials: F
authors.lastname: Gierski
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Azorin
authors.forename: Frédéric
authors.initials: F
authors.lastname: Limosin
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000068180:Aripiprazole; D001569:Benzodiazepines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects*; D003024:Clozapine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D015331:Cohort Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077152:Olanzapine; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011446:Prospective Studies; D015363:Quinolones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D018967:Risperidone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy*; D015431:Weight Loss / Q000187:drug effects
chemical_list: D014150:Antipsychotic Agents; D010879:Piperazines; D015363:Quinolones; D001569:Benzodiazepines; D000068180:Aripiprazole; D003024:Clozapine; D018967:Risperidone; D000077152:Olanzapine